Stock AUTL AUTOLUS THERAPEUTICS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Autolus Therapeutics plc

Equities

AUTL

US05280R1005

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-28 pm EDT 		5-day change 1st Jan Change
4.02 USD +2.55% Intraday chart for Autolus Therapeutics plc +3.88% -37.58%
May. 23 Tech Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading MT
May. 21 European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading MT

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Truist Securities Adjusts Price Target on Autolus Therapeutics to $10 From $9, Keeps Buy Rating
MT
Needham Adjusts Autolus Therapeutics Price Target to $9 From $8, Maintains Buy Rating
MT
Needham Adjusts Autolus Therapeutics' Price Target to $8 From $7, Maintains Buy Rating
MT
Goldman Sachs Raises Price Target on Autolus Therapeutics to $4.80 From $3.20, Maintains Neutral Rating
MT
Deutsche Bank Initiates Coverage on Autolus Therapeutics With Buy Rating, $10 Price Target
MT
Truist Securities Adjusts Price Target on Autolus Therapeutics to $9 From $6, Maintains Buy Rating
MT
Wells Fargo Adjusts Price Target on Autolus Therapeutics to $6 From $8, Maintains Overweight Rating
MT
Wells Fargo Assumes Autolus Therapeutics at Overweight With $8 Price Target
MT
Mizuho Adjusts Price Target on Autolus Therapeutics to $12 From $18, Maintains Buy Rating
MT
Needham Lowers Price Target on Autolus Therapeutics to $7 From $12, Maintains Buy Rating
MT
Syncona portfolio firm hits 70% remission rate goal in leukaemia trial
AN
European Equities Follow US Markets Lower on Interest Rate Concerns
MT
Truist Securities Trims Autolus Therapeutics' Price Target to $10 From $11, Maintains Buy Rating
MT
Truist Securities Adjusts Price Target for Autolus Therapeutics to $11 From $13, Maintains Buy Rating
MT
HC Wainwright Adjusts Autolus Therapeutics' Price Target to $11 From $13, Reiterates Buy Rating
MT
AUTOLUS THERAPEUTICS : Goldman Sachs Adjusts Price Target on Autolus Therapeutics to $5.50 From $9.50, Maintains Neutral Rating
MT
AUTOLUS THERAPEUTICS : Jefferies Lifts Autolus Therapeutics to Buy From Hold, Price Target to $12 From $6
MT
AUTOLUS THERAPEUTICS : Needham & Co Adjusts Autolus Therapeutics PT to $21 From $26, Maintains Buy Rating
MT
AUTOLUS THERAPEUTICS : Redburn Downgrades Autolus Therapeutics to Neutral from Buy
MT
AUTOLUS THERAPEUTICS : JPMorgan Downgrades Autolus Therapeutics to Neutral From Overweight, Adjusts Price Target to $9 From $24
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AUTL Stock
  4. News Autolus Therapeutics plc
  5. Analyst Reco.